Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Jaguar Health Launches Neonorm Dog on Amazon, Expanding Animal-Health Product Franchise

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

Jaguar Health, Inc. Announces Reverse Stock Split

Jaguar Health Receives Fee Waivers from FDA

Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float

Jaguar Health Announces a Special Stock Dividend

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi

Jaguar Health Targets Mid-2027 MVID NDA Filing as Crofelemer Intestinal Failure Program Advances